 |
|
COMMENTS & OPINIONS
Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation
Houssem Hmouda, MD;
Chaker Ben Salem, MD;
Kamel Bouraoui, MD;
Letaief Jemni, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In the October 2006 issue of the Archives, Hidayat et al1 addressed an alarming issue related to vancomycin treatment failures for infections caused by vancomycin-susceptible MRSA strains with a relatively high MIC. They suggested the use of combination or alternative therapy for invasive infections.
In fact, the pertinent issue is relevant to alternative therapy. Should we use newer agents or should we go back and reexamine the efficacy of older therapies against MRSA? We might suggest an answer with reference to our clinical findings published 13 years ago by Jemni et al.2 In this series, 26 of 27 patients treated with trimethoprim-sulfamethoxazole for MRSA infections were cured. Newer antistaphylococcal agents certainly have a proven efficacy but are not routinely prescribed. In addition, resistance to quinupristin-dalfopristin and linezolid has emerged.3 Therefore, it is justified to reexamine the . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTER
Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation—Reply
Annie Wong-Beringer, Levita K. Hidayat, and Donald I. Hsu
Arch Intern Med. 2007;167(11):1208-1209.
EXTRACT
| FULL TEXT
RELATED ARTICLE
High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections: Efficacy and Toxicity
Levita K. Hidayat, Donald I. Hsu, Ryan Quist, Kimberly A. Shriner, and Annie Wong-Beringer
Arch Intern Med. 2006;166(19):2138-2144.
ABSTRACT
| FULL TEXT
|
